TMSB10

TMSB10 Full Name

thymosin beta 10

TMSB10 Introduction

TMSB10 (thymosin beta 10) is a highly conserved actin-sequestering protein encoded by the TMSB10 gene and belongs to the β-thymosin family of small acidic peptides. Composed of only 43 amino acids, TMSB10 functions as an intrinsically disordered protein that dynamically changes conformation when interacting with G-actin, allowing it to regulate cytoskeletal remodeling, cell morphology, and intracellular motility. Although structurally similar to thymosin β4, TMSB10 demonstrates distinct tissue distribution and disease associations, particularly during embryonic development and tumor progression. Studies have shown that TMSB10 is highly expressed in developing organs such as fetal kidney tubules, salivary glands, and endocrine pancreatic tissues, suggesting an important role in tissue morphogenesis and differentiation. Its presence in both cytoplasmic vesicles and nuclear compartments further indicates that TMSB10 is not merely a structural protein, but also a multifunctional regulator involved in secretion, migration, and cellular stress adaptation. Because cytoskeletal dysregulation is a central feature of both developmental abnormalities and aggressive cancers, TMSB10 has become increasingly relevant in translational research focused on metastasis, immune regulation, and therapeutic resistance.

One of the major reasons TMSB10 has attracted attention in oncology is its consistent overexpression across multiple human malignancies, including lung adenocarcinoma, glioblastoma, breast cancer, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, and renal cell carcinoma. Functional studies indicate that TMSB10 promotes tumor cell proliferation, invasion, epithelial–mesenchymal transition (EMT), and metastatic behavior by activating signaling pathways such as PI3K/Akt/mTOR, MAPK, IL6/JAK/STAT3, and HIF-1. In glioma models, elevated TMSB10 expression has been linked to mesenchymal transition, enhanced stem-like characteristics, resistance to apoptosis, and accelerated tumor aggressiveness. Experimental knockdown of TMSB10 suppresses cell migration and colony formation while improving responsiveness to MEK inhibitors and anti-PD1 immunotherapy, highlighting its emerging role as a therapeutic sensitization target. In hepatocellular carcinoma, TMSB10 expression is detected in the vast majority of tumor tissues and correlates strongly with poor prognosis, supporting its potential value as a prognostic biomarker. These findings are particularly important for researchers seeking molecular indicators that connect cytoskeletal remodeling with oncogenic signaling and treatment resistance within a single targetable pathway.

Beyond its direct effects on tumor cells, TMSB10 is increasingly recognized as an important regulator of the tumor immune microenvironment. Recent studies demonstrate that TMSB10 can drive the polarization of tumor-associated macrophages (TAMs) toward the immunosuppressive M2 phenotype, thereby promoting immune evasion and tumor progression. In lung adenocarcinoma, high TMSB10 expression is associated with increased TAM infiltration, advanced TNM stage, larger tumor size, and shorter overall survival. Mechanistically, TMSB10 suppresses pro-inflammatory cytokines such as IL-6, IL-12, and TNF-α while enhancing IL-10 expression through activation of the PI3K/Akt signaling axis. Pan-cancer analyses further reveal strong correlations between TMSB10 and immune checkpoint molecules including PD-1 and PD-L1, as well as associations with reduced tumor purity and altered immune cell infiltration. These discoveries position TMSB10 at the intersection of cancer biology and immunotherapy research, especially for investigators attempting to understand why some tumors fail to respond to checkpoint blockade therapies. As precision oncology increasingly shifts toward biomarker-guided treatment strategies, TMSB10 is emerging as both a prognostic indicator and a potential therapeutic target capable of influencing tumor growth, immune suppression, and drug sensitivity simultaneously.

Alternate Names for TMSB10

TMSB10; thymosin beta 10; migration-inducing protein 12; TB10; thymosin beta-10; MIG12; PTMB10; migration-inducing gene 12; THYB10

• 1.Faa G, et al.; Thymosin β4 and β10 Expression in Human Organs during Development: A Review. Cells. 2024, 13(13):1115.
  2.Zeng J, et al.; Thymosin β10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma. Respir Res. 2020, 21(1):328.